Group 1 - The article highlights CorMedix Inc. (NASDAQ: CRMD) as a focus for investment, particularly due to its flagship product, an antimicrobial catheter, which is entering full commercialization [2] - The Biotech Forum, led by Bret, offers a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions on trade ideas and weekly market commentary [2] - The article emphasizes the importance of real-time trading ideas and discussions among seasoned biotech investors within the forum [1] Group 2 - The analyst has a beneficial long position in CRMD shares, indicating confidence in the company's potential [3] - The article does not provide specific financial metrics or performance data for CorMedix, focusing instead on the investment community's interest and engagement [2][3]